Format

Send to

Choose Destination
Minerva Urol Nefrol. 2010 Dec;62(4):411-23.

mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.

Author information

1
Department of Urology, Lukas Hospital, Neuss, Germany. holger.gerullis@gmx.net

Abstract

The potent inhibitor of the mammalian target of rapamycin, temsirolimus, comprises for cell cycle, angiogenesis and proliferation and has proven beneficial in the treatment of advanced renal cell carcinoma (RCC). Temsirolimus is officially approved for first line therapy in high risk previously untreated mRCC patients. This review summarizes the current clinical role of temsirolimus in the treatment of advanced renal cell carcinoma with regard to pharmacological features, toxicity and tolerability. It particularily discusses quality of life issues as important outcome parameters in palliative treatment of patients with mRCC and gives an outlook on current clinical developments regarding possible future combining/ sequencing strategies of temsirolimus.

PMID:
20944541
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Minerva Medica
Loading ...
Support Center